Literature DB >> 12379677

Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

Jiraprapa Wipasa1, Huji Xu, Morris Makobongo, Michelle Gatton, Anthony Stowers, Michael F Good.   

Abstract

Immunity induced by the 19-kDa fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) is dependent on high titers of specific antibodies present at the time of challenge and a continuing active immune response postinfection. However, the specificity of the active immune response postinfection has not been defined. In particular, it is not known whether anti-MSP1(19) antibodies that arise following infection alone are sufficient for protection. We developed systems to investigate whether an MSP1(19)-specific antibody response alone both prechallenge and postchallenge is sufficient for protection. We were able to exclude antibodies with other specificities, as well as any contribution of MSP1(19)-specific CD4(+) T cells acting independent of antibody, and we concluded that an immune response focused solely on MSP1(19)-specific antibodies is sufficient for protection. The data imply that the ability of natural infection to boost an MSP1(19)-specific antibody response should greatly improve vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379677      PMCID: PMC130409          DOI: 10.1128/IAI.70.11.6013-6020.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Indirect IL-4 pathway in type 1 immunity.

Authors:  Alexey Y Karulin; Maike D Hesse; Hualin C Yip; Paul V Lehmann
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

2.  Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.

Authors:  C Hirunpetcharat; J H Tian; D C Kaslow; N van Rooijen; S Kumar; J A Berzofsky; L H Miller; M F Good
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

3.  Deletion of Plasmodium berghei-specific CD4+ T cells adoptively transferred into recipient mice after challenge with homologous parasite.

Authors:  C Hirunpetcharat; M F Good
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S).

Authors:  J Hu-Li; J Ohara; C Watson; W Tsang; W E Paul
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.

Authors:  C Hirunpetcharat; P Vukovic; X Q Liu; D C Kaslow; L H Miller; M F Good
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

7.  Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

Authors:  J H Tian; L H Miller; D C Kaslow; J Ahlers; M F Good; D W Alling; J A Berzofsky; S Kumar
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

8.  The role of TH1 and TH2 cells in a rodent malaria infection.

Authors:  A W Taylor-Robinson; R S Phillips; A Severn; S Moncada; F Y Liew
Journal:  Science       Date:  1993-06-25       Impact factor: 47.728

9.  Inhibition of B lymphocyte activation by interferon-gamma.

Authors:  D S Reynolds; W H Boom; A K Abbas
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

10.  Immunization against malaria with a recombinant protein.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1994-02       Impact factor: 2.280

View more
  9 in total

1.  Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.

Authors:  Sheetij Dutta; Deep C Kaushal; Lisa A Ware; Sunil K Puri; Nuzhat A Kaushal; Atul Narula; D S Upadhyaya; David E Lanar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

3.  Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.

Authors:  Pimmada Jeamwattanalert; Yuvadee Mahakunkijcharoen; Leera Kittigul; Pakpimol Mahannop; Sathit Pichyangkul; Chakrit Hirunpetcharat
Journal:  Clin Vaccine Immunol       Date:  2007-02-21

4.  Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice.

Authors:  Shigeto Yoshida; Hitomi Araki; Takashi Yokomine
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

5.  Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.

Authors:  Danielle I Stanisic; Laura B Martin; Xue Q Liu; David Jackson; Juan Cooper; Michael F Good
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

6.  Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

Authors:  A Rainczuk; T Scorza; P M Smooker; T W Spithill
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.

Authors:  Sanjay Singh; Michael C Kennedy; Carole A Long; Allan J Saul; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.

Authors:  Sai Lata De; Samuel May; Keshav Shah; Michelle Slawinski; Siriruk Changrob; Shulin Xu; Samantha J Barnes; Patchanee Chootong; Francis B Ntumngia; John H Adams
Journal:  Vaccine       Date:  2021-04-08       Impact factor: 3.641

9.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.